Clinical trials: Advanced Non-small Cell Lung Cancer
Lung Cancer
ERCC1 Targeted Trial
Lung cancer is the leading cause of cancer death in the UK, leading to 34 000 deaths each year (22% of cancer deaths). Non-small cell lung cancer (NSCLC) is the most common histology, accounting for approximately 80% of cases and…
- Trial name
- ET (NCT00801736)
- Testing
- Cisplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- University College, London
NSCLC
18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC
This study is a diagnostic study. Subjects were enrolled from clinical stage IIIB or IV NSCLC patients who received standard first-line chemotherapy combined with PD-1 monoclonal antibody immunotherapy and received 18F-FDG PET/CT…
- Trial name
- NCT04996927
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Non-small Cell Lung Cancer, First-line Treatment
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
This prospective, unicentric, open-labe phase I study is to evaluate the effects of autologous cytokine-induced killer cell immunotherapy combination with PD-1 inhibitor and chemotherapy in the first-line treatment of…
- Trial name
- NCT03987867
- Testing
- CIK cell, Sintilimab Injection, Pemetrexed
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1…
- Trial name
- NCT03646994
- Testing
- Crizotinib
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hunan Province Tumor Hospital
Lung Neoplasms
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
- Trial name
- NCT05203276
- Testing
- Envafolimab, Endostar
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The First People's Hospital of Lianyungang
Locally Advanced or Metastatic NSCLC
Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole
To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects.
- Trial name
- NCT05631678
- Testing
- Rifampicin; ASK120067, ASK120067;itraconazole
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Non-Small Cell Lung Cancer
Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients
Several reports have examined Programmed Death 1 (PD-1) expression on tumor-infiltrating T-cells, and its correlation with prognosis has been discussed.
- Trial name
- NCT02758314
- Testing
- Evaluation of PD-1/PDL-1 expression.
- Where
- Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung Cancer
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.
- Trial name
- APRIL (NCT07565987)
- Testing
- SBRT in stage III NSCLC
- Where
- India
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Metastatic Melanoma, Metastatic Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
It is nowadays well established that the immune system can profoundly influence disease outcome in cancer patients. Increasing evidence is indeed showing that patients displaying spontaneous T cell-mediated immune response…
- Conditions
- Metastatic Melanoma, Metastatic Breast Cancer, Advanced Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- SERPENTINE (NCT04941365)
- Testing
- single arm
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
- Trial name
- PEMBREIZH (NCT05321212)
- Where
- 2 sites in France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Advanced Non-small Cell Lung Cancer, EGFR Mutation
A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor…
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Trial name
- NCT06329895
- Testing
- BAY2927088, Dabigatran etexilate, Rosuvastatin
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bayer
Lung Cancer
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination…
- Trial name
- NCT00193323
- Testing
- Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Locally Advanced or Metastatic NSCLC
Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects
To evaluate the pharmacokinetic characteristics of ASK120067 and CCB4580030 after the single oral administration of ASK120067 in fast and after a high-fat meal in healthy Chinese subjects, and to evaluate the effect of food on…
- Trial name
- NCT04360915
- Testing
- ASK120067, ASK120067 in fed condition
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.
- Trial name
- NCT04974879
- Testing
- Osimertinib Oral Tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Qingdao Central Hospital